[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"NeuroSync, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":119},{"warningLetters":4,"total":118},[5,31,50,76,96],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},897,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-09T04:00:00Z\">05\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurosync-inc-705489-05092025\">NeuroSync, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gary Gregory\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NeuroSync, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>118 Washington St, Ste 14\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holliston\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01746\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 705489\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Gregory:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Holliston, MA, on January 6, 2025, through February 5, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures EYE-SYNC, consisting of a virtual reality headset and tablet computer which performs eye assessments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received your response, dated February 27, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically:\u003C\u002Fp>\u003Cp>a. You failed to verify your device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.4, which requires that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” For example:\u003C\u002Fp>\u003Cp>i. Your EYE-SYNC Design Input Requirements, DIR-10101, Rev 007, includes a design requirement related to tracking performance accuracy that states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, your TR-10332 Eye Tracking Performance Test Result – \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identifies that the average accuracy was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the test report was approved on August 16, 2021, even though this requirement was not met.\u003C\u002Fp>\u003Cp>ii. Your EYE-SYNC Software Requirements Specification, SRS-10102, states, “If the data quality is low the users will be warned. If the data quality is insufficient, the users are alerted, and the analysis result score is not offered to the user for the given assessment.” However, you did not have any testing to verify that low quality data results in a warning to the user, and that insufficient data quality does not present a score.\u003C\u002Fp>\u003Cp>b. You failed to identify, document, validate or where appropriate verify, review, and approve of design changes before their implementation, as required by 21 CFR 820.30(i). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.7.iii, which requires that “Changes are identified, documented, validated or where appropriate verified, reviewed, and approved prior to the implementation of the change.” For example:\u003C\u002Fp>\u003Cp>i. ECO 24-0033 released EYE-SYNC tablet software version 1.2.9_25_1234 to correct an issue which allowed the device to continue collecting data in the event the headset is removed, potentially resulting in the incorrect color of the data quality indicator. However, associated software testing in TR-10139, Rev 34 did not verify that version 1.2.9_25_1234 corrected this issue.\u003C\u002Fp>\u003Cp>c. You failed to establish design inputs to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.2 Requirements, which explain that design inputs “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>For example:\u003C\u002Fp>\u003Cp>i. EYE-SYNC Design Input Requirements, DIR-10101, Rev 007, lists requirements that are not related to the current device. For example, requirement C2.3, Latch Fit, states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and requirement C4.2 states “Device shall have USB \u003Cstrong>(b)(4)\u003C\u002Fstrong> of similar form factor to Eye Tracker Unit (ETU).” Both of these requirements are outdated and refer to Model X02 of EYE-SYNC, which was replaced by model X03 in April 2021.\u003C\u002Fp>\u003Cp>d. You failed to validate your device design to ensure that devices conform to defined user needs and intended uses, as required by 21 CFR 820.30(g). For example,\u003C\u002Fp>\u003Cp>i. Your Risk Management Procedure, SOP-10011, Rev 002, states that the level of risk is determined by Risk Priority Numbers (RPN) and that the design \u003Cstrong>(b)(4)\u003C\u002Fstrong> will use the severity and occurrence rating scales described in the procedure. However, your software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, RA-10110, Rev 006, does not use RPNs, and the impact and probability scale used to calculate inherent and residual risk are not adequately defined within SOP-10011.\u003C\u002Fp>\u003Cp>We reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. We understand that you opened several CAPAs to identify necessary updates to your design control processes; however, your response does not provide sufficient detail to ensure that these failures will not recur and that your current devices meet all your design control requirements. For example, your CAPA 202502053 for design change indicates that Test Reports and ECOs issued from February 4-19, 2025, will be reviewed but does not explain why older reports are not being reviewed.\u003C\u002Fp>\u003Cp>Our review also noted that the EYE-SYNC system, as released to users beginning April 2021, uses either the \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the eye tracking unit of the EYE-SYNC. We encourage you to perform a thorough review of your current design to ensure any changes made to the EYE-SYNC after FDA clearances have been reviewed properly. For example, for the above hardware design change, we would expect your firm to have documentation of the appropriate verification, review, and approval of design changes before their implementation. In response to this Warning Letter, please provide a timeline of when all proposed corrective actions to your design control processes will be completed, including when you will complete a review of your current device to ensure all specified design requirements are met.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, including implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems, as required by 21 CFR 820.100(a)(5). For example, CAPA 202110081 was opened on October 8, 2021, to address higher than expected assessment scores. The CAPA included a corrective action that stated, “To correct the core non-conformity, the raw data capture implementation of the eye tracker software must be updated to appropriately capture head and eye position data to accurately reflect scores within the typical range.” During the inspection, your firm indicated that a software correction to the eye tracker software had not been made.\u003C\u002Fp>\u003Cp>We reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation to demonstrate that you have completed a corrective action for the above CAPA.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. You have not implemented your Supplier Management Procedure, SOP-10025, Rev 004. Specifically:\u003C\u002Fp>\u003Cp>a. Your vendor who manufactures the EYE-SYNC’s Eye Tracker, p\u002Fn P-10114, has not been evaluated since March 15, 2022, despite your Supplier Management Procedure and Supplier Status Form, F-10093, identifying that the supplier requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> performance evaluations.\u003C\u002Fp>\u003Cp>b. Your software vendor who supplies the sensor which is placed in the Eye Tracker is not listed on your firm's Approved Supplier List and has not been approved or evaluated as per your procedure.\u003C\u002Fp>\u003Cp>We reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation that the above vendors have successfully completed evaluations as per your procedures.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a). For example, your firm’s Release for Shipment Procedure, SOP-10029, Rev 003, describes the activities needed to release a finished device, which include \"visual inspection of product to ascertain that all specified operations are completed and to detect any visible quality problems.” During the inspection, you confirmed the employee tasked with finished device inspection works \u003Cstrong>(b)(4)\u003C\u002Fstrong> and does not review test reports or perform a visual inspection as required by your procedure.\u003C\u002Fp>\u003Cp>We reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation to show that your corrective actions have been implemented to ensure visual inspection requirements are currently being performed as required by your procedure.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s EYE‐SYNC Eye Tracker devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>Failure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example, on or about September 19, 2023, your firm replaced\u002Fremoved Pico 2 components of EYE‐SYNC devices. The devices would stall or freeze, resulting in a delay of diagnostic procedure or inability to assess a patient. CDRH’s risk assessment concluded the devices failing to perform as intended may cause temporary or medically reversible adverse health consequences or a remote probability of serious adverse health consequences. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health posed by the device, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s response to Observation 12 of the FDA‐483, dated February 27, 2025, is not adequate. You have not submitted Reports of Correction or Removal to FDA as of this date.\u003C\u002Fp>\u003Cp>Our inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the EYE-SYNC Model X03 devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for EYE-SYNC Model X03 do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of EYE-SYNC Model X03 (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology on the label of EYE-SYNC X03 (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>Your response dated February 27, 2025, is not adequate. Your firm promised to obtain mock-ups of revised labeling for review by March 27, 2025, and to obtain UDIs for issuing agency \u003Cstrong>(b)(4)\u003C\u002Fstrong>, update procedures to include them, and submit GUDID entries. However, you have not provided revised labels as evidence that your labels will include valid UDIs as of this date.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Refer to \u003Cstrong>CMS case #705489\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer, at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGary Gregory\n\nRecipient Title\n\nPresident & CEO\n\nNeuroSync, Inc.\n\n118 Washington St, Ste 14\n\nHolliston, MA 01746\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 705489\nMay 9, 2025\nDear Mr. Gregory:\nDuring an inspection of your firm located in Holliston, MA, on January 6, 2025, through February 5, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures EYE-SYNC, consisting of a virtual reality headset and tablet computer which performs eye assessments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received your response, dated February 27, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically:\na. You failed to verify your device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.4, which requires that “(b)(4).” For example:\ni. Your EYE-SYNC Design Input Requirements, DIR-10101, Rev 007, includes a design requirement related to tracking performance accuracy that states, “(b)(4).” However, your TR-10332 Eye Tracking Performance Test Result – (b)(4), identifies that the average accuracy was (b)(4), and the test report was approved on August 16, 2021, even though this requirement was not met.\nii. Your EYE-SYNC Software Requirements Specification, SRS-10102, states, “If the data quality is low the users will be warned. If the data quality is insufficient, the users are alerted, and the analysis result score is not offered to the user for the given assessment.” However, you did not have any testing to verify that low quality data results in a warning to the user, and that insufficient data quality does not present a score.\nb. You failed to identify, document, validate or where appropriate verify, review, and approve of design changes before their implementation, as required by 21 CFR 820.30(i). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.7.iii, which requires that “Changes are identified, documented, validated or where appropriate verified, reviewed, and approved prior to the implementation of the change.” For example:\ni. ECO 24-0033 released EYE-SYNC tablet software version 1.2.9_25_1234 to correct an issue which allowed the device to continue collecting data in the event the headset is removed, potentially resulting in the incorrect color of the data quality indicator. However, associated software testing in TR-10139, Rev 34 did not verify that version 1.2.9_25_1234 corrected this issue.\nc. You failed to establish design inputs to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). You did not implement your Design Controls, Software Design, Development and Maintenance Procedure, Section 6.2 Requirements, which explain that design inputs “…(b)(4).”\nFor example:\ni. EYE-SYNC Design Input Requirements, DIR-10101, Rev 007, lists requirements that are not related to the current device. For example, requirement C2.3, Latch Fit, states “(b)(4),” and requirement C4.2 states “Device shall have USB (b)(4) of similar form factor to Eye Tracker Unit (ETU).” Both of these requirements are outdated and refer to Model X02 of EYE-SYNC, which was replaced by model X03 in April 2021.\nd. You failed to validate your device design to ensure that devices conform to defined user needs and intended uses, as required by 21 CFR 820.30(g). For example,\ni. Your Risk Management Procedure, SOP-10011, Rev 002, states that the level of risk is determined by Risk Priority Numbers (RPN) and that the design (b)(4) will use the severity and occurrence rating scales described in the procedure. However, your software (b)(4), RA-10110, Rev 006, does not use RPNs, and the impact and probability scale used to calculate inherent and residual risk are not adequately defined within SOP-10011.\nWe reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. We understand that you opened several CAPAs to identify necessary updates to your design control processes; however, your response does not provide sufficient detail to ensure that these failures will not recur and that your current devices meet all your design control requirements. For example, your CAPA 202502053 for design change indicates that Test Reports and ECOs issued from February 4-19, 2025, will be reviewed but does not explain why older reports are not being reviewed.\nOur review also noted that the EYE-SYNC system, as released to users beginning April 2021, uses either the (b)(4) or (b)(4) as the eye tracking unit of the EYE-SYNC. We encourage you to perform a thorough review of your current design to ensure any changes made to the EYE-SYNC after FDA clearances have been reviewed properly. For example, for the above hardware design change, we would expect your firm to have documentation of the appropriate verification, review, and approval of design changes before their implementation. In response to this Warning Letter, please provide a timeline of when all proposed corrective actions to your design control processes will be completed, including when you will complete a review of your current device to ensure all specified design requirements are met.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, including implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems, as required by 21 CFR 820.100(a)(5). For example, CAPA 202110081 was opened on October 8, 2021, to address higher than expected assessment scores. The CAPA included a corrective action that stated, “To correct the core non-conformity, the raw data capture implementation of the eye tracker software must be updated to appropriately capture head and eye position data to accurately reflect scores within the typical range.” During the inspection, your firm indicated that a software correction to the eye tracker software had not been made.\nWe reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation to demonstrate that you have completed a corrective action for the above CAPA.\n3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. You have not implemented your Supplier Management Procedure, SOP-10025, Rev 004. Specifically:\na. Your vendor who manufactures the EYE-SYNC’s Eye Tracker, p\u002Fn P-10114, has not been evaluated since March 15, 2022, despite your Supplier Management Procedure and Supplier Status Form, F-10093, identifying that the supplier requires (b)(4) performance evaluations.\nb. Your software vendor who supplies the sensor which is placed in the Eye Tracker is not listed on your firm's Approved Supplier List and has not been approved or evaluated as per your procedure.\nWe reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation that the above vendors have successfully completed evaluations as per your procedures.\n4. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a). For example, your firm’s Release for Shipment Procedure, SOP-10029, Rev 003, describes the activities needed to release a finished device, which include \"visual inspection of product to ascertain that all specified operations are completed and to detect any visible quality problems.” During the inspection, you confirmed the employee tasked with finished device inspection works (b)(4) and does not review test reports or perform a visual inspection as required by your procedure.\nWe reviewed your firm response dated February 27, 2025, and concluded that it is not adequate. You have not provided documentation to show that your corrective actions have been implemented to ensure visual inspection requirements are currently being performed as required by your procedure.\nOur inspection also revealed that your firm’s EYE‐SYNC Eye Tracker devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example, on or about September 19, 2023, your firm replaced\u002Fremoved Pico 2 components of EYE‐SYNC devices. The devices would stall or freeze, resulting in a delay of diagnostic procedure or inability to assess a patient. CDRH’s risk assessment concluded the devices failing to perform as intended may cause temporary or medically reversible adverse health consequences or a remote probability of serious adverse health consequences. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health posed by the device, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s response to Observation 12 of the FDA‐483, dated February 27, 2025, is not adequate. You have not submitted Reports of Correction or Removal to FDA as of this date.\nOur inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the EYE-SYNC Model X03 devices do not bear such a UDI.\nSpecifically, the labels for EYE-SYNC Model X03 do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of EYE-SYNC Model X03 (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses (b)(4) technology on the label of EYE-SYNC X03 (see 21 CFR 801.40(a)(2)).\nYour response dated February 27, 2025, is not adequate. Your firm promised to obtain mock-ups of revised labeling for review by March 27, 2025, and to obtain UDIs for issuing agency (b)(4), update procedures to include them, and submit GUDID entries. However, you have not provided revised labels as evidence that your labels will include valid UDIs as of this date.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Refer to CMS case #705489 when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer, at karen.archdeacon@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","NeuroSync, Inc.","neurosync-inc-705489-05092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurosync-inc-705489-05092025","2026-10-26T08:09:32.048717+00:00","Warning Letter","Issued","2025-05-20","705489","Medical Devices","Gary Gregory","2026-08-19T16:46:13.996+00:00","VIA Electronic Mail","2025-05-09",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},2811,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2022-03-15T13:20:00Z\">03\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-28T05:00:00Z\">02\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurofield-inc-621767-02282022\">NeuroField, Inc.\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nicholas J. Dogris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Co-Founder\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NeuroField, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>386 West Line Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bishop\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93514-3413\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nicholasdogris@verizon.net\"> nicholasdogris@verizon.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 621767\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 28, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Dogris:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations located at 386 W. Line Street, Bishop, CA from September 28 through October 6, 2021. During the inspection, an FDA Investigator determined that your firm manufactures neurostimulation and electroencephalogram (EEG) signal processing devices, including the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, and software products NeuroField64, and NeuroField EEG. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection and review of the available information, including the firm’s website, revealed that the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, NeuroField64, and NeuroField EEG are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for these devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency per 21 CFR 807.81(b).\u003C\u002Fp>\n\n\u003Cp>Neurofield, Inc., has registered and listed the NeuroField X3000 and NeuroField Q21 as biofeedback devices under 21 CFR 882.5050. A biofeedback device classified under 21 CFR 882.5050 is identified as “an instrument that provides a visual or auditory signal corresponding to the status of one or more of a patient's physiological parameters (e.g., brain alpha wave activity, muscle activity, skin temperature, etc.) so that the patient can control voluntarily these physiological parameters.” The device is classified as class II and subject to general and special controls. Per 21 CFR 882.5050(b), this device type is exempt from the premarket notification procedures (510(k) when it is a prescription battery powered device that is indicated for relaxation training and muscle reeducation and prescription use, subject to 21 CFR 882.9.\u003C\u002Fp>\n\n\u003Cp>However, based on our review of materials collected during the inspection and other available information, including statements on your firm’s website, http:\u002F\u002Fneurofield.org (last visited 01\u002F24\u002F2022), as described below, these devices are intended for uses that exceed or otherwise differ from the classification codified at 21 CFR 882.5050, such that premarket notification is required prior to introduction or delivery for introduction of these devices into interstate commerce for commercial distribution per 21 CFR 882.9.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>NeuroField X3000\u002FX3000 Plus\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Statements on your firm’s website and the manual for the NeuroField64 X3000 indicate the NeuroField X3000\u002FX3000 Plus is intended for stimulation-based treatment use, which is an intended use beyond the scope of the biofeedback device classification per 21 CFR 882.5050.\u003C\u002Fp>\n\n\u003Cp>Examples of such statements from your website include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“The X3000 Plus is a low intensity 4 channel pEMF (pulsed electromagnetic field) generator using four 400-wind coil packs for precision placement anywhere on the body.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The frequency range from 0.31Hz to 300,000Hz, output intensity range from 1-100 microTesla (uT), and the ability to generate sine, triangle, and square waveforms means the X3000 Plus is one of the most flexible pEMF generators in the industry.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“[T]he X3000 Plus is the first pEMF system in the world to combine stimulation with z-score, norm referenced operant conditioning methods.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“If you wish to run stimulation therapies, take a look at our X3000 or Genesis.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The X3000 is a STIMULATION ONLY unit, and it does not record any data.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“Package Contents: X3000 Plus Stim Unit”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of such statements from the manual for the NeuroField64 X3000 include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“The NeuroField X3000 is pEMF stimulator that is designed to deliver low intensity pEMF to the person.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The X3000 ships with four pEMF coils. Plug them into the front of the unit. Once connected they are ready to use.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“This chapter will give you a step-by-step tutorial of how to deliver pEMF with the X3000.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>NeuroField Q21\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Statements on your website and the manual for the NeuroField64 Q21 indicate the NeuroField Q21 is intended for use as an electroencephalograph (EEG), which is a device use that falls within classification regulation 21 CFR 882.1400 and is not exempt from premarket notification requirements.\u003C\u002Fp>\n\n\u003Cp>Examples of such statements from the firm’s website include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“The Q21 is a 19+1 channel Electroencephalogram with a low noise floor of 0.25 μV peak to peak from 0.1 to 10.0Hz, meaning that you can record EEG without worrying about noise contamination.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The Q21 is a Quantitative Electroencephalograph . . . .”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of such statements from the manual for the NeuroField64 Q21 include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“At the time of the QEEG, ask client to remove any earrings or clips\u002Fpins in the hair that would sit beneath the cap.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The ‘Q2x QEEG User Interface’ will open. This is where you can start and stop your scans.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>NeuroField64 and NeuroField EEG\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, FDA notes that your firm’s website and materials collected during the inspection include references to software products called “NeuroField64” and “NeuroField EEG.” Statements on your firm’s website and in the manuals for the NeuroField64, NeuroField64 X3000, and NeuroField64 Q21 describe the use of the NeuroField64 and NeuroField EEG software products in conjunction with NeuroField X3000\u002FX3000 Plus and NeuroField Q21, as well as functions of the software products such that the software products appear to meet the definition of device under section 201(h) of the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of such statements from your firm’s website include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“NeuroField64 is a 64-bit program that brings together all of NeuroField’s hardware products and features into one platform!”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The X3000 Plus is a software-controlled system which is fully customizable all the way down to the easy-to-use patient database.” The specifications for X3000 Plus identify NeuroField64 as the compatible software.\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“X3000 Package Details . . . Access to NeuroField64”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“NeuroField EEG is a 64-bit program module, used in conjunction with NeuroField’s Q21 Amplifier that marks the beginning of our journey into EEG recording and analysis.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“Record EEG in a pristine 24-bit resolution with a frequency range of 0.5 - 70 Hz range.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of such statements from the manuals for the NeuroField64, NeuroField64 X3000, and NeuroField64 Q21 include but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“This chapter will give you a step-by-step tutorial of how to deliver pEMF with the X3000. The following tutorial requires that you have installed NeuroField64 on your computer.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“In NeuroField64 you can not only acquire stand-alone EEG using either device, you can also use either the Q20 or Q21 to synchronize EEG with stimulation (pEMF, tACS, or both) during a single session.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“This chapter will give you a step-by-step tutorial of how to record EEG with the Q21 EEG amplifier. The following tutorial requires that you have installed NeuroField64 on your computer.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You are also promoting NeuroField devices on other websites and social media (Facebook, Twitter, and Instagram), for uses that are beyond the scope of the biofeedback device classification at 21 CFR 882.5050, such as recording QEEG data, neurostimulation, and treatment of various medical conditions. During a review of the websites https:\u002F\u002Fschoolofneurotherapy.com and https:\u002F\u002Fneurofieldneurotherapy.com, which each contain information indicating ownership or control of the websites by NeuroField CEO Nicholas Dogris, FDA observed claims related to NeuroField devices, including but not limited to the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Neurofield 2-Day EEG &amp; ERP Course . . . This two-day course is dedicated to the clinical use of event related potentials, the measure of electrical potential created from time-locked events, as well as Neurofield EEG, a recording and EEG analysis platform that quantifies data into QEEG format.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“pEMF, also known as pulsed electromagnetic field stimulation, creates a difference in how our\u003C\u002Fem>&nbsp;\u003Cem>\u003Cem>neurons fire and can be like physical therapy for the brain. The X3000 is programmable so that we\u003C\u002Fem>\u003C\u002Fem>&nbsp;\u003Cem>\u003Cem>can choose the frequency to be delivered from between 0.31 Hz to 300,000 Hz, depending on the desired treatment outcome.” \u003C\u002Fem>\u003C\u002Fem>Below this statement, there is a link to “LEARN ABOUT OUR PEMF EQUIPMENT” that takes the user to the firm’s Products webpage https:\u002F\u002Fneurofield.org\u002Fneurofieldproducts.\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“PEMF is an incredibly versatile treatment. We place the coils around the head for brainwave entrainment and coherence. This is because the consistent rhythm of the stimulation helps neurons synchronize. We also frequently place coils on the belly for inflammation reduction, and around joints for arthritis, fibromyalgia, and other ailments.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“we often use the system (hardware and software) developed by Neurofield Inc., which is synchronized neurofeedback and neurostimulation training. We have found that this modality is much faster than other forms of neurofeedback-only, since we can first demonstrate to the brain what we would like it to achieve, and then reward those results (neurofeedback-only models do not demonstrate to the brain how to behave, which makes for a much longer period for the brain to catch on).”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“PTSD responds well to neurotherapy. By addressing the physiology of the symptom, we are able to\u003C\u002Fem>&nbsp;\u003Cem>address the physics behind the conditioned response. After a number of sessions, it is common our\u003C\u002Fem>&nbsp;\u003Cem>clients experience a reduction in the disturbing symptoms of PTSD, becoming able to resume a normal life.” \u003C\u002Fem>Below this statement, there is a link to “LEARN MORE ABOUT NEUROSTIMULATION” that takes the user to the NEUROSTIMULATION\u002FNEUROMODULATION webpage. This webpage includes the following statement: “Neuromodulation not only sets us apart, but because of Neurofield’s inventions, there are hundreds of clinicians using Neurofield pEMF equipment in their clinical practices.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Our office requests that NeuroField cease any activities that result in the adulteration or misbranding of the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, NeuroField64, and NeuroField EEG, such as the commercial distribution of the devices for uses that exceed or otherwise differ from the classification codified at 21 CFR 882.5050, including the uses discussed above. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>.The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response on October 26, 2021 from \u003Cstrong>(b)(6)\u003C\u002Fstrong>, concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm. Your firm indicated that you plan to submit an updated response by April 15, 2022. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately establish complaint handling procedures as you did not conduct or document complaint investigation as required by your Corrective and Preventative and Complaint Handling Standard Operating Procedure, QAP-0600, Rev. 2. For example, our investigator reviewed fifteen Complaint Handling Forms that are associated with RMA reports related to coil damages, broken jack screws, X3000 unit not powering up, power cable loose, and software issues and found your complaint records did not always include details of the complaint, dates and results of investigation, reason investigation was not conducted, software name, unique device identifier or universal product code, or address of the complainant.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm committed to updating complaint records and related procedures and forms to add clarity and directions for processing complaints. You indicated that you have retrained all your personnel and added a reviewer to ensure the completeness of your complaint handling process. However, the complaint records you provided in your response still lack adequate details and it is not clear how you evaluated for possible failure of a device to meet its specifications. In response to this letter, please include updates and supporting records of your corrective actions as they progress, including retrospective review of all potential complaints.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your CAPA procedure, Corrective and Preventative Action and Complaint Handling Standard Operating Procedure, QAP-0600 Rev.2, has not been adequately established and your CAPAs did not correct or prevent the identified quality problem from recurring. For example,\u003C\u002Fp>\n\n\u003Cp>a. CAPA0001 was opened on 2\u002F23\u002F2018 to address complaint handling deficiencies related to 23 service reports on coil damages, broken jack screws, X3000 not powering up, power cable loose and no response to software input. Your firm’s QA approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 10\u002F17\u002F2019, the same date you listed for Corrective Actions(s) taken, such as SOP update, retraining and staff reassignment. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm had not evaluated all 23 service reports for potential complaint investigation per your complaint handling process. Furthermore, the investigator identified additional complaint handling deficiencies.\u003C\u002Fp>\n\n\u003Cp>b. CAPA0003 was opened on 2\u002F23\u002F2018 to address the failure to establish a quality policy and objectives for quality, such as not appointing a management representative and not conducting internal audits by an individual who does not have direct responsibility. Your firm’s QA approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 5\u002F24\u002F2018, the same date you listed for Corrective Actions(s) taken, such as SOP update, retraining and organizational chart update. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm did not conduct any internal audits.\u003C\u002Fp>\n\n\u003Cp>c. CAPA0007 was opened on 2\u002F23\u002F2018 to address failure to establish records of acceptable suppliers and contractors. Your firm’s QA Approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 3\u002F25\u002F2019, the same date listed for Corrective Action(s) taken, such as SOP and Form updates, critical supplier list update, and staff reassignment of duties. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found you had not evaluated your critical suppliers per your procedures.\u003C\u002Fp>\n\n\u003Cp>d. CAPA0008 was opened on 2\u002F23\u002F2018 to address lack of equipment calibration and maintenance records for equipment such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s QA Approval of Closure and CAPA\u002FComplaint Effectivity dates are listed as 11\u002F5\u002F2020, the same date you listed for Corrective Action(s) taken to update your Production and Process Control procedure, QCP-0200, Rev. 2. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm you did not conduct calibration of equipment used during manufacturing of your devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm committed to updating your CAPA procedure and training your employees. Your firm provided a brief summary of CAPAs, and corresponding corrective\u002Fpreventive action taken, and verification activities, but they do not provide sufficient details to fully assess the adequacy of your corrective actions to date and lack documentation to demonstrate that you have corrected your violations. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress. Our website, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn\">https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn\u003C\u002Fa> provides training and references which you may find useful in complying with the corrective and preventive action and other quality system requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50. Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform supplier evaluations of all twelve of your critical suppliers on your Approved Supplier List (ASL), PUR100-1, that were scheduled to have supplier evaluation completed in 2019 and 2020. Your critical suppliers include \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>; they provide PCB boards and printed circuit boards required for manufacturing the NeuroField X3000 and NeuroFieldQ21. We also note that your firm’s Purchasing and Supplier Control procedure, PUR100 Rev. 1, does not clearly define how your firm determines what makes a supplier noncritical (NC) or critical (C.) and your firm could not provide documentation to show how you determined the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> suppliers\u002Fvendors on your ASL to be either critical or noncritical.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm committed to reevaluating all your critical suppliers and identify any other suppliers that needs to be re-evaluated. You also committed to updating your procedure to include criteria to distinguish critical and non-critical suppliers and add a mechanism to alert suppliers of such re-evaluation. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure equipment is routinely calibrated, inspected, checked and maintained, as required by 21 CFR § 820.72(a). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to ensure that equipment used during manufacturing of the NeuroField X3000\u002FX3000 Plus and NeuroField Q21 are routinely calibrated, inspected, checked, and maintained. Affected equipment include \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>used during your in-process or finished device manufacturing activities. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration was done in 2019 with next due date of 10\u002F2020, but our current inspection found you have not performed recalibration since 2019. It is unclear how you determine what equipment needs maintenance and at what frequency.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm committed to retraining all personnel on your Production and Process Control procedure, QCP200, Rev. 2 where you state \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment calibration requirements are already included. Although calibration is mentioned in your SOP, QCP200 Rev. 2, it lacks details on provisions for handling, preservation and storage of equipment so that its accuracy and fitness for use are maintained. Furthermore, you did not submit any corresponding training records and supporting information on how you would track and monitor calibration activities to ensure your equipment is suitable for its intended purposes and is capable of producing valid results. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to adequately establish procedures for management review, as required by 21 CFR 820.20(c). Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Management Review of the Quality System Meetings procedure, QAP-300 Rev.1, effective 2\u002F8\u002F2019, requires that a formal Management Review Meeting will be held on an \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. Your firm failed to implement the procedure and did not conduct any management review meetings.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm committed to reviewing and updating the above procedure to ensure that it meets the requirements of 21 CFR 820.20(c) and training all staff on the SOP. You also stated you’ll conduct management review by the end of 2021. However, you did not submit any supporting documentation of your corrections. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to adequately establish procedures for quality audits, as required by 21 CFR § 820.22. Specifically,\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Internal Quality Audit procedure, QAP200 Rev. 1, effective 3\u002F21\u002F19, requires that the audit program will ensure that during the year, each applicable procedure will be audited at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to complete any internal audit since the procedure has been in effect. In addition, your procedure does not have requirements that audits shall be conducted by individuals who do not have direct responsibilities for the matters being audited.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm committed to completing the internal audits and to finding an external auditor to complete an audit of your firm’s Quality Management System. However, you did not submit supporting documentation of your corrections. In response to this letter please submit any updated internal audit procedures and scheduled audit dates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via e-mail to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS case #621767 when replying. If you have questions regarding the content of this letter, please contact Compliance Officer, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\u003Cbr>\nDeputy Director OHT5: Office of Neurological and Physical\u003Cbr>\nMedicine Devices Office of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003C\u002Fp>\n\n\u003Cp>Cc: Mr. Bradley W. Wiitala\u003Cbr>\nDirector of Research &amp; Development (R&amp;D) and Co-Founder\u002FCo-Owner\u003Cbr>\nBrad@neurofield.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nNicholas J. Dogris\n\nRecipient Title\n\nCEO & Co-Founder\u002FCo-Owner\n\nNeuroField, Inc.\n\n386 West Line Street\n\nBishop, CA 93514-3413\n\nUnited States\n\nnicholasdogris@verizon.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 621767\n\nFebruary 28, 2022\n\nDear Mr. Dogris:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations located at 386 W. Line Street, Bishop, CA from September 28 through October 6, 2021. During the inspection, an FDA Investigator determined that your firm manufactures neurostimulation and electroencephalogram (EEG) signal processing devices, including the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, and software products NeuroField64, and NeuroField EEG. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body.\n\nOur inspection and review of the available information, including the firm’s website, revealed that the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, NeuroField64, and NeuroField EEG are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for these devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency per 21 CFR 807.81(b).\n\nNeurofield, Inc., has registered and listed the NeuroField X3000 and NeuroField Q21 as biofeedback devices under 21 CFR 882.5050. A biofeedback device classified under 21 CFR 882.5050 is identified as “an instrument that provides a visual or auditory signal corresponding to the status of one or more of a patient's physiological parameters (e.g., brain alpha wave activity, muscle activity, skin temperature, etc.) so that the patient can control voluntarily these physiological parameters.” The device is classified as class II and subject to general and special controls. Per 21 CFR 882.5050(b), this device type is exempt from the premarket notification procedures (510(k) when it is a prescription battery powered device that is indicated for relaxation training and muscle reeducation and prescription use, subject to 21 CFR 882.9.\n\nHowever, based on our review of materials collected during the inspection and other available information, including statements on your firm’s website, http:\u002F\u002Fneurofield.org (last visited 01\u002F24\u002F2022), as described below, these devices are intended for uses that exceed or otherwise differ from the classification codified at 21 CFR 882.5050, such that premarket notification is required prior to introduction or delivery for introduction of these devices into interstate commerce for commercial distribution per 21 CFR 882.9.\n\nNeuroField X3000\u002FX3000 Plus\n\nStatements on your firm’s website and the manual for the NeuroField64 X3000 indicate the NeuroField X3000\u002FX3000 Plus is intended for stimulation-based treatment use, which is an intended use beyond the scope of the biofeedback device classification per 21 CFR 882.5050.\n\nExamples of such statements from your website include but are not limited to:\n\n“The X3000 Plus is a low intensity 4 channel pEMF (pulsed electromagnetic field) generator using four 400-wind coil packs for precision placement anywhere on the body.”\n\n“The frequency range from 0.31Hz to 300,000Hz, output intensity range from 1-100 microTesla (uT), and the ability to generate sine, triangle, and square waveforms means the X3000 Plus is one of the most flexible pEMF generators in the industry.”\n\n“[T]he X3000 Plus is the first pEMF system in the world to combine stimulation with z-score, norm referenced operant conditioning methods.”\n\n“If you wish to run stimulation therapies, take a look at our X3000 or Genesis.”\n\n“The X3000 is a STIMULATION ONLY unit, and it does not record any data.”\n\n“Package Contents: X3000 Plus Stim Unit”\n\nExamples of such statements from the manual for the NeuroField64 X3000 include but are not limited to:\n\n“The NeuroField X3000 is pEMF stimulator that is designed to deliver low intensity pEMF to the person.”\n\n“The X3000 ships with four pEMF coils. Plug them into the front of the unit. Once connected they are ready to use.”\n\n“This chapter will give you a step-by-step tutorial of how to deliver pEMF with the X3000.”\n\nNeuroField Q21\n\nStatements on your website and the manual for the NeuroField64 Q21 indicate the NeuroField Q21 is intended for use as an electroencephalograph (EEG), which is a device use that falls within classification regulation 21 CFR 882.1400 and is not exempt from premarket notification requirements.\n\nExamples of such statements from the firm’s website include but are not limited to:\n\n“The Q21 is a 19+1 channel Electroencephalogram with a low noise floor of 0.25 μV peak to peak from 0.1 to 10.0Hz, meaning that you can record EEG without worrying about noise contamination.”\n\n“The Q21 is a Quantitative Electroencephalograph . . . .”\n\nExamples of such statements from the manual for the NeuroField64 Q21 include but are not limited to:\n\n“At the time of the QEEG, ask client to remove any earrings or clips\u002Fpins in the hair that would sit beneath the cap.”\n\n“The ‘Q2x QEEG User Interface’ will open. This is where you can start and stop your scans.”\n\nNeuroField64 and NeuroField EEG\n\nIn addition, FDA notes that your firm’s website and materials collected during the inspection include references to software products called “NeuroField64” and “NeuroField EEG.” Statements on your firm’s website and in the manuals for the NeuroField64, NeuroField64 X3000, and NeuroField64 Q21 describe the use of the NeuroField64 and NeuroField EEG software products in conjunction with NeuroField X3000\u002FX3000 Plus and NeuroField Q21, as well as functions of the software products such that the software products appear to meet the definition of device under section 201(h) of the Act.\n\nExamples of such statements from your firm’s website include but are not limited to:\n\n“NeuroField64 is a 64-bit program that brings together all of NeuroField’s hardware products and features into one platform!”\n\n“The X3000 Plus is a software-controlled system which is fully customizable all the way down to the easy-to-use patient database.” The specifications for X3000 Plus identify NeuroField64 as the compatible software.\n\n“X3000 Package Details . . . Access to NeuroField64”\n\n“NeuroField EEG is a 64-bit program module, used in conjunction with NeuroField’s Q21 Amplifier that marks the beginning of our journey into EEG recording and analysis.”\n\n“Record EEG in a pristine 24-bit resolution with a frequency range of 0.5 - 70 Hz range.”\n\nExamples of such statements from the manuals for the NeuroField64, NeuroField64 X3000, and NeuroField64 Q21 include but are not limited to:\n\n“This chapter will give you a step-by-step tutorial of how to deliver pEMF with the X3000. The following tutorial requires that you have installed NeuroField64 on your computer.”\n\n“In NeuroField64 you can not only acquire stand-alone EEG using either device, you can also use either the Q20 or Q21 to synchronize EEG with stimulation (pEMF, tACS, or both) during a single session.”\n\n“This chapter will give you a step-by-step tutorial of how to record EEG with the Q21 EEG amplifier. The following tutorial requires that you have installed NeuroField64 on your computer.”\n\nYou are also promoting NeuroField devices on other websites and social media (Facebook, Twitter, and Instagram), for uses that are beyond the scope of the biofeedback device classification at 21 CFR 882.5050, such as recording QEEG data, neurostimulation, and treatment of various medical conditions. During a review of the websites https:\u002F\u002Fschoolofneurotherapy.com and https:\u002F\u002Fneurofieldneurotherapy.com, which each contain information indicating ownership or control of the websites by NeuroField CEO Nicholas Dogris, FDA observed claims related to NeuroField devices, including but not limited to the following:\n\n“Neurofield 2-Day EEG & ERP Course . . . This two-day course is dedicated to the clinical use of event related potentials, the measure of electrical potential created from time-locked events, as well as Neurofield EEG, a recording and EEG analysis platform that quantifies data into QEEG format.”\n\n“pEMF, also known as pulsed electromagnetic field stimulation, creates a difference in how our neurons fire and can be like physical therapy for the brain. The X3000 is programmable so that we can choose the frequency to be delivered from between 0.31 Hz to 300,000 Hz, depending on the desired treatment outcome.” Below this statement, there is a link to “LEARN ABOUT OUR PEMF EQUIPMENT” that takes the user to the firm’s Products webpage https:\u002F\u002Fneurofield.org\u002Fneurofieldproducts.\n\n“PEMF is an incredibly versatile treatment. We place the coils around the head for brainwave entrainment and coherence. This is because the consistent rhythm of the stimulation helps neurons synchronize. We also frequently place coils on the belly for inflammation reduction, and around joints for arthritis, fibromyalgia, and other ailments.”\n\n“we often use the system (hardware and software) developed by Neurofield Inc., which is synchronized neurofeedback and neurostimulation training. We have found that this modality is much faster than other forms of neurofeedback-only, since we can first demonstrate to the brain what we would like it to achieve, and then reward those results (neurofeedback-only models do not demonstrate to the brain how to behave, which makes for a much longer period for the brain to catch on).”\n\n“PTSD responds well to neurotherapy. By addressing the physiology of the symptom, we are able to address the physics behind the conditioned response. After a number of sessions, it is common our clients experience a reduction in the disturbing symptoms of PTSD, becoming able to resume a normal life.” Below this statement, there is a link to “LEARN MORE ABOUT NEUROSTIMULATION” that takes the user to the NEUROSTIMULATION\u002FNEUROMODULATION webpage. This webpage includes the following statement: “Neuromodulation not only sets us apart, but because of Neurofield’s inventions, there are hundreds of clinicians using Neurofield pEMF equipment in their clinical practices.”\n\nOur office requests that NeuroField cease any activities that result in the adulteration or misbranding of the NeuroField X3000\u002FX3000 Plus, NeuroField Q21, NeuroField64, and NeuroField EEG, such as the commercial distribution of the devices for uses that exceed or otherwise differ from the classification codified at 21 CFR 882.5050, including the uses discussed above. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm.The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\n\nThis inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response on October 26, 2021 from (b)(6), concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm. Your firm indicated that you plan to submit an updated response by April 15, 2022. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a). Specifically,\n\nYour firm failed to adequately establish complaint handling procedures as you did not conduct or document complaint investigation as required by your Corrective and Preventative and Complaint Handling Standard Operating Procedure, QAP-0600, Rev. 2. For example, our investigator reviewed fifteen Complaint Handling Forms that are associated with RMA reports related to coil damages, broken jack screws, X3000 unit not powering up, power cable loose, and software issues and found your complaint records did not always include details of the complaint, dates and results of investigation, reason investigation was not conducted, software name, unique device identifier or universal product code, or address of the complainant.\n\nWe reviewed your firm’s response and determined that it is not adequate. Your firm committed to updating complaint records and related procedures and forms to add clarity and directions for processing complaints. You indicated that you have retrained all your personnel and added a reviewer to ensure the completeness of your complaint handling process. However, the complaint records you provided in your response still lack adequate details and it is not clear how you evaluated for possible failure of a device to meet its specifications. In response to this letter, please include updates and supporting records of your corrective actions as they progress, including retrospective review of all potential complaints.\n\n2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically,\n\nYour CAPA procedure, Corrective and Preventative Action and Complaint Handling Standard Operating Procedure, QAP-0600 Rev.2, has not been adequately established and your CAPAs did not correct or prevent the identified quality problem from recurring. For example,\n\na. CAPA0001 was opened on 2\u002F23\u002F2018 to address complaint handling deficiencies related to 23 service reports on coil damages, broken jack screws, X3000 not powering up, power cable loose and no response to software input. Your firm’s QA approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 10\u002F17\u002F2019, the same date you listed for Corrective Actions(s) taken, such as SOP update, retraining and staff reassignment. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm had not evaluated all 23 service reports for potential complaint investigation per your complaint handling process. Furthermore, the investigator identified additional complaint handling deficiencies.\n\nb. CAPA0003 was opened on 2\u002F23\u002F2018 to address the failure to establish a quality policy and objectives for quality, such as not appointing a management representative and not conducting internal audits by an individual who does not have direct responsibility. Your firm’s QA approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 5\u002F24\u002F2018, the same date you listed for Corrective Actions(s) taken, such as SOP update, retraining and organizational chart update. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm did not conduct any internal audits.\n\nc. CAPA0007 was opened on 2\u002F23\u002F2018 to address failure to establish records of acceptable suppliers and contractors. Your firm’s QA Approval of Closure and CAPA\u002FComplaint Effectivity Evaluation dates are listed as 3\u002F25\u002F2019, the same date listed for Corrective Action(s) taken, such as SOP and Form updates, critical supplier list update, and staff reassignment of duties. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found you had not evaluated your critical suppliers per your procedures.\n\nd. CAPA0008 was opened on 2\u002F23\u002F2018 to address lack of equipment calibration and maintenance records for equipment such as (b)(4). Your firm’s QA Approval of Closure and CAPA\u002FComplaint Effectivity dates are listed as 11\u002F5\u002F2020, the same date you listed for Corrective Action(s) taken to update your Production and Process Control procedure, QCP-0200, Rev. 2. Although your record states you found the CAPA to be effective, it is unclear what effectiveness check criteria were established and met. During the current inspection, the investigator found that your firm you did not conduct calibration of equipment used during manufacturing of your devices.\n\nWe reviewed your firm’s response and determined that it is not adequate. Your firm committed to updating your CAPA procedure and training your employees. Your firm provided a brief summary of CAPAs, and corresponding corrective\u002Fpreventive action taken, and verification activities, but they do not provide sufficient details to fully assess the adequacy of your corrective actions to date and lack documentation to demonstrate that you have corrected your violations. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress. Our website, https:\u002F\u002Fwww.fda.gov\u002Ftraining-and-continuing-education\u002Fcdrh-learn provides training and references which you may find useful in complying with the corrective and preventive action and other quality system requirements.\n\n3. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50. Specifically,\n\nYour firm failed to perform supplier evaluations of all twelve of your critical suppliers on your Approved Supplier List (ASL), PUR100-1, that were scheduled to have supplier evaluation completed in 2019 and 2020. Your critical suppliers include (b)(4) and (b)(4); they provide PCB boards and printed circuit boards required for manufacturing the NeuroField X3000 and NeuroFieldQ21. We also note that your firm’s Purchasing and Supplier Control procedure, PUR100 Rev. 1, does not clearly define how your firm determines what makes a supplier noncritical (NC) or critical (C.) and your firm could not provide documentation to show how you determined the (b)(4) suppliers\u002Fvendors on your ASL to be either critical or noncritical.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm committed to reevaluating all your critical suppliers and identify any other suppliers that needs to be re-evaluated. You also committed to updating your procedure to include criteria to distinguish critical and non-critical suppliers and add a mechanism to alert suppliers of such re-evaluation. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress.\n\n4. Failure to establish procedures to ensure equipment is routinely calibrated, inspected, checked and maintained, as required by 21 CFR § 820.72(a). Specifically,\n\nYour firm failed to ensure that equipment used during manufacturing of the NeuroField X3000\u002FX3000 Plus and NeuroField Q21 are routinely calibrated, inspected, checked, and maintained. Affected equipment include (b)(4) used during your in-process or finished device manufacturing activities. For example, your (b)(4) calibration was done in 2019 with next due date of 10\u002F2020, but our current inspection found you have not performed recalibration since 2019. It is unclear how you determine what equipment needs maintenance and at what frequency.\n\nWe reviewed your firm’s response and determined that it is not adequate. Your firm committed to retraining all personnel on your Production and Process Control procedure, QCP200, Rev. 2 where you state (b)(4) equipment calibration requirements are already included. Although calibration is mentioned in your SOP, QCP200 Rev. 2, it lacks details on provisions for handling, preservation and storage of equipment so that its accuracy and fitness for use are maintained. Furthermore, you did not submit any corresponding training records and supporting information on how you would track and monitor calibration activities to ensure your equipment is suitable for its intended purposes and is capable of producing valid results. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\n\n5. Failure to adequately establish procedures for management review, as required by 21 CFR 820.20(c). Specifically,\n\nYour Management Review of the Quality System Meetings procedure, QAP-300 Rev.1, effective 2\u002F8\u002F2019, requires that a formal Management Review Meeting will be held on an (b)(4) basis. Your firm failed to implement the procedure and did not conduct any management review meetings.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm committed to reviewing and updating the above procedure to ensure that it meets the requirements of 21 CFR 820.20(c) and training all staff on the SOP. You also stated you’ll conduct management review by the end of 2021. However, you did not submit any supporting documentation of your corrections. In response to this letter, please include updates and supporting records of implementation of these corrective actions as they progress.\n\n6. Failure to adequately establish procedures for quality audits, as required by 21 CFR § 820.22. Specifically,\n\nYour Internal Quality Audit procedure, QAP200 Rev. 1, effective 3\u002F21\u002F19, requires that the audit program will ensure that during the year, each applicable procedure will be audited at least (b)(4). Your firm failed to complete any internal audit since the procedure has been in effect. In addition, your procedure does not have requirements that audits shall be conducted by individuals who do not have direct responsibilities for the matters being audited.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm committed to completing the internal audits and to finding an external auditor to complete an audit of your firm’s Quality Management System. However, you did not submit supporting documentation of your corrections. In response to this letter please submit any updated internal audit procedures and scheduled audit dates and supporting records of implementation of these corrective actions as they progress.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nYour firm's response should be sent via e-mail to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS case #621767 when replying. If you have questions regarding the content of this letter, please contact Compliance Officer, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\n\nDeputy Director OHT5: Office of Neurological and Physical\n\nMedicine Devices Office of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc: Mr. Bradley W. Wiitala\n\nDirector of Research & Development (R&D) and Co-Founder\u002FCo-Owner\n\nBrad@neurofield.com","NeuroField, Inc.","neurofield-inc-621767-02282022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurofield-inc-621767-02282022","2026-10-26T08:09:31.962457+00:00","2022-03-15","621767","Nicholas J. Dogris","2026-08-20T02:06:28.901+00:00","2022-02-28",{"id":51,"raw":52,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":67,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":71,"issuing_office":56,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},3353,[53,54,55,56,57,13,58,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-27T04:00:00Z\">04\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurohydrate-llc-613092-04272021\">NeuroHydrate LLC \u003C\u002Fa>","Office of Human and Animal Food Operations East – Division 1","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurohydrate-llc-613092-06212021\">\u003Ctime datetime=\"2021-06-23T04:00:00Z\">06\u002F23\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hamid Sami\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founding Partner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NeuroHydrate LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4637 Main St, Unit 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bridgeport\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06606-1838\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East – Division 1\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS# 613092\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMr. Justin Higgins, Managing Partner\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Sami and Mr. Higgins:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fneurohydrate.com\u002F On January 2021 and has determined that you take orders there for the product “HM-FORMULA”. The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1) (B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003Cbr>\n? The product description pages for your “HM-FORMULA” product state:\u003Cbr>\no “NeuroHydrate’s HM-Formula is…specifically designed for Headache and Migraine prevention.”\u003Cbr>\no “NeuroHydrate’s HM-Formula is…designed to reduce the frequency, severity and duration of headache and migraine”\u003C\u002Fp>\n\n\u003Cp>? The frequently asked questions (FAQs) page of your webpage under the question “What is HMFormula?” states:\u003Cbr>\no “HM-Formula (Headache Migraine Formula) is…designed to prevent headache and migraine…”\u003Cbr>\no “The ingredients…were selected based upon their medical efficacy in headache and migraine prevention…”\u003C\u002Fp>\n\n\u003Cp>? The HM-Formula product reviews page of your webpage:\u003Cbr>\no In response to a customer review dated May 30, 2019, your firm responded, “…HMFormula… contains a combination of proven…high-potency migraine prevention ingredients...”\u003Cbr>\no In response to a customer review dated January 08, 2018, your firm responded, “Our research and development is solely with the migraine prevention ingredients…used in the NeuroHydrate’s HM-Formula and their effect on chronic and frequent episodic migraine patients over time.”\u003Cbr>\no In response to a customer review dated August 01, 2016, your firm responded, “…we made a superior migraine prevention product....”\u003Cbr>\no In response to a customer review dated July 26, 2016, your firm responded, “We encourage you to compare HM-Formula’s ingredient label to other migraine prevention products.”\u003Cbr>\no A customer review dated December 7, 2020, states, “I have struggled with migraines my entire life…” to which your firm responded, “It is fantastic that NeuroHydrate’s MPT Program is working well for you…”\u003C\u002Fp>\n\n\u003Cp>? The MPT Program page of your webpage which includes a 90-day supply of your HM-Formula product states, “…our Migraine Prevention Therapy Program (MPT)…”\u003C\u002Fp>\n\n\u003Cp>? The HM-Formula product Quality of Life Customer Survey page of your webpage states:\u003Cbr>\no “NeuroHydrate created HM-Formula (HMF), a new migraine supplement…”\u003Cbr>\no “The underlying raw ingredients used in HM-Formula are…proven effective for migraine prevention…”\u003Cbr>\no “The first objective was to measure patients “before and after” migraine experience using HM-Formula. Customers reported a 25% pain scale improvement…”\u003Cbr>\no “NeuroHydrate believes that if migraine prevention supplements…are effective in migraine prevention…”\u003C\u002Fp>\n\n\u003Cp>? The ingredients clinical studies and research and development page of your webpage states, “…consider using NeuroHydrate’s HM-Formula in first step migraine prevention.”\u003C\u002Fp>\n\n\u003Cp>? The NeuroHydrate Core Ingredients page of your webpage states:\u003Cbr>\no “Randomized double-blind clinical trials demonstrated that a daily dose of 200 milligrams of Riboflavin is superior in preventing migraine…”\u003Cbr>\no “In a double-blind trial, 50 milligrams per day of B6 was effective in decreasing premenstrual depression…and is used for the prevention of nausea in migraineurs…”\u003Cbr>\no “In a randomized clinical trial, 300 milligrams per day of CoQ10 reduced the frequency of migraine by more than 50% in nearly half of all the participants…”\u003Cbr>\no “In two placebo-controlled studies, Omega-3 fatty acids performed significantly better than placebo in reducing headache frequency and intensity. In another double-blind study, with 27 medically diagnosed adolescents suffering from migraine, use of Omega 3’s showed marked improvement in reducing headache frequency, duration, and severity…”\u003C\u002Fp>\n\n\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003Cbr>\n\u003Cbr>\nThe matters cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the matters cited in this letter. Failure to promptly correct these matters may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within 15 working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the U.S. Food and Drug Administration, Attention: Scott R. Izyk, Compliance Officer, 1 Winners Circle, Suite 140, Albany, NY 12205 or by e-mail (preferred) to scott.izyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Hamid Sami\n\nRecipient Title\n\nFounding Partner\n\nNeuroHydrate LLC\n\n4637 Main St, Unit 5\n\nBridgeport, CT 06606-1838\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East – Division 1\n\nUnited States\n\nWARNING LETTER\n\nCMS# 613092\n\nMr. Justin Higgins, Managing Partner\n\nDear Mr. Sami and Mr. Higgins:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fneurohydrate.com\u002F On January 2021 and has determined that you take orders there for the product “HM-FORMULA”. The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1) (B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\n? The product description pages for your “HM-FORMULA” product state:\n\no “NeuroHydrate’s HM-Formula is…specifically designed for Headache and Migraine prevention.”\n\no “NeuroHydrate’s HM-Formula is…designed to reduce the frequency, severity and duration of headache and migraine”\n\n? The frequently asked questions (FAQs) page of your webpage under the question “What is HMFormula?” states:\n\no “HM-Formula (Headache Migraine Formula) is…designed to prevent headache and migraine…”\n\no “The ingredients…were selected based upon their medical efficacy in headache and migraine prevention…”\n\n? The HM-Formula product reviews page of your webpage:\n\no In response to a customer review dated May 30, 2019, your firm responded, “…HMFormula… contains a combination of proven…high-potency migraine prevention ingredients...”\n\no In response to a customer review dated January 08, 2018, your firm responded, “Our research and development is solely with the migraine prevention ingredients…used in the NeuroHydrate’s HM-Formula and their effect on chronic and frequent episodic migraine patients over time.”\n\no In response to a customer review dated August 01, 2016, your firm responded, “…we made a superior migraine prevention product....”\n\no In response to a customer review dated July 26, 2016, your firm responded, “We encourage you to compare HM-Formula’s ingredient label to other migraine prevention products.”\n\no A customer review dated December 7, 2020, states, “I have struggled with migraines my entire life…” to which your firm responded, “It is fantastic that NeuroHydrate’s MPT Program is working well for you…”\n\n? The MPT Program page of your webpage which includes a 90-day supply of your HM-Formula product states, “…our Migraine Prevention Therapy Program (MPT)…”\n\n? The HM-Formula product Quality of Life Customer Survey page of your webpage states:\n\no “NeuroHydrate created HM-Formula (HMF), a new migraine supplement…”\n\no “The underlying raw ingredients used in HM-Formula are…proven effective for migraine prevention…”\n\no “The first objective was to measure patients “before and after” migraine experience using HM-Formula. Customers reported a 25% pain scale improvement…”\n\no “NeuroHydrate believes that if migraine prevention supplements…are effective in migraine prevention…”\n\n? The ingredients clinical studies and research and development page of your webpage states, “…consider using NeuroHydrate’s HM-Formula in first step migraine prevention.”\n\n? The NeuroHydrate Core Ingredients page of your webpage states:\n\no “Randomized double-blind clinical trials demonstrated that a daily dose of 200 milligrams of Riboflavin is superior in preventing migraine…”\n\no “In a double-blind trial, 50 milligrams per day of B6 was effective in decreasing premenstrual depression…and is used for the prevention of nausea in migraineurs…”\n\no “In a randomized clinical trial, 300 milligrams per day of CoQ10 reduced the frequency of migraine by more than 50% in nearly half of all the participants…”\n\no “In two placebo-controlled studies, Omega-3 fatty acids performed significantly better than placebo in reducing headache frequency and intensity. In another double-blind study, with 27 medically diagnosed adolescents suffering from migraine, use of Omega 3’s showed marked improvement in reducing headache frequency, duration, and severity…”\n\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nThe matters cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nYou should take prompt action to correct the matters cited in this letter. Failure to promptly correct these matters may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin 15 working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\n\nPlease send your reply to the U.S. Food and Drug Administration, Attention: Scott R. Izyk, Compliance Officer, 1 Winners Circle, Suite 140, Albany, NY 12205 or by e-mail (preferred) to scott.izyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1","NeuroHydrate LLC","neurohydrate-llc-613092-04272021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurohydrate-llc-613092-04272021","2026-10-26T08:09:31.998428+00:00","Closed Out","2021-05-18","613092","Drugs","2021-06-23","Mr. Hamid Sami","2026-08-20T03:08:05.626+00:00","United Parcel Service","2021-04-27",{"id":77,"raw":78,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},1767,[79,80,81,11,82,13,13,13],"\u003Ctime datetime=\"2023-11-07T14:20:00Z\">11\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-27T04:00:00Z\">10\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurotris-inc-dba-a1-engineering-659244-10272023\">Neurotris, Inc. dba A1 Engineering\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony “Tony” E. Picciano\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Neurotris, Inc. dba A1 Engineering\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>30 Mauchly Ste A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tony@neurotris.com\"> tony@neurotris.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 659244\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 27, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Picciano:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Neurotris, Inc. (Neurotris or NeurotriS or “the firm”), located in Irvine, CA, on April 4, 2023, through April 25, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of Class II Powered Muscle Stimulator devices such as the Neurotris SX or SVX Series Facial Body Systems, which may also be referred to as the Neurotris Body System. These medical devices include, but are not limited to, the SX2500 (Picowave), SX3800, SX4500, SVX650, PICO Toner, and accessories such as electrodes, conductive gels, and spray. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received your response, dated May 6, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection and review of the available information, including the firm’s website, www.neurotris.com, revealed that the Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, PICO Toner, and accessories such as electrodes (ANMA lift, Probes, Silver Facial Sculpting Gloves, Facial Pads), conductive gels, and spray, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for these devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)(1)).\u003C\u002Fp>\n\n\u003Cp>You currently have a clearance for the Body System (models SX101 and 0S2911) dated February 26, 2019, as a prescription device, under K182440. The Body System was cleared as a Powered Muscle Stimulator for muscle conditioning under 21 CFR 890.5850 product code NGX for the following indications:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>“The Body System is intended for muscle conditioning to stimulate healthy muscles. The Body System is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. The Body System is intended to be operated by a trained professional who is present to monitor treatment.”\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the evidence reviewed at the April 2023 inspection and other available information, including statements on your firm’s website [https:\u002F\u002Fwww.neurotris.com] and social media [Facebook], last reviewed on August 13, 2023, as described below, the devices cited in this letter have intended uses that exceed or otherwise differ from your 510(k) clearance for the Body System device and the classification codified at 21 CFR 890.5850, such that premarket notification is required prior to introduction or delivery for introduction of these devices into interstate commerce for commercial distribution per 21 CFR 807.81(a). Additionally, your devices appear to have different technological characteristics than the original 510(k) cleared device, including, among others, differences in power sources, number of channels, and device accessories, which could significantly affect the safety or effectiveness of the device. Further, the following changes represent significant changes or modifications outside the scope of the K182440 clearance in the design, components, method of manufacture, or intended use of your cleared device, which could also significantly affect its safety and effectiveness.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The original Body System devices (models SX101 and 0S2911) were cleared under K182440. A review of your website and manuals for your current Neurotris devices, the SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner show that these new devices have different technical characteristics than those of the SX101 and OS2911. These differences include variations between the number of channels compared to the cleared devices. In addition, models SX101 and OS2911 are mains powered but the PICO Toner II is battery powered. It also appears that the circuitry of the devices may be different from the cleared device. All of these changes in the technical characteristics create potential differences in the electrical safety and electromagnetic compatibility of your devices compared to the tested and cleared device, which may lead to risks associated with electric shock, excessive temperatures, burns, and interference. Such changes and modifications could significantly affect the safety and effectiveness of these devices. Therefore, such technical differences would require a new 510(k).\u003C\u002Fp>\n\n\u003Cp>Additionally, there are significant differences between how your originally cleared devices and the new devices are intended to be used, according to the labeling. As described in “Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff” (fda.gov), changes to labeling, including the Indications for Use, require review in a new 510(k). The guidance notes that the decision to submit a new 510(k) may apply not only to changes to the indications for use statement of the labeling, but also to changes to other sections of the labeling, such as the directions for use of the device. The original devices were cleared as Powered Muscle Stimulators for muscle conditioning under 21 CFR 890.5850 product code NGX. The cleared indication for use states, \u003Cem>“The Body System is intended for muscle conditioning to stimulate healthy muscles.”\u003C\u002Fem> However, a review of your Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner manuals show that the intended use of these devices is \u003Cem>“to stimulate nerves and muscles, causing muscle contraction for esthetic beautification.”\u003C\u002Fem> The stimulation of nerves for aesthetic purposes is a significant change in how and where the device is intended to be used from your cleared 510(k) device. Stimulation of nerves as opposed to muscles raises new questions of safety and effectiveness requiring FDA review prior to marketing. Additionally, stimulation of nerves exceeds the intended use definition of devices classified under 21 CFR 890.5850 for powered muscle stimulators.\u003C\u002Fp>\n\n\u003Cp>Furthermore, there is significant risk related to the new anatomical areas of use that are promoted by your firm. The original cleared Body System manuals (models SX101 and 0S2911) have the following warnings against use on the chest, significant portions of the face, and neck:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Stimulation should not be applied over the neck or mouth. Severe spasm of the laryngeal and pharyngeal muscles may occur and the contractions may be strong enough to close the airway or cause difficulty in breathing.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“Stimulation should not be applied transthoracically in that the introduction of electrical current in the heart may cause cardiac arrhythmias”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“Stimulation should not be applied transcerebrally\"\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Yet, multiple statements on your firm’s website, social media, and user manuals promote the use of Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner on these prohibited areas.\u003C\u002Fp>\n\n\u003Cp>Examples of promotional statements from your website, social media, and manual that are beyond the clearance of your device under 21 CFR 890.5850 for Powered Muscle Stimulators include but are not limited to (refers to Neurotris website labeling unless otherwise noted):\u003C\u002Fp>\n\n\u003Cp>\u003Cu>SX2500 (Picowave)\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>Auto Mode 2 BUILD (FACE LIFTING)\u003C\u002Fem> (Manual)\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“This client is having an amazing result with NEUROTRIS Picowave Microcurrent and Rezenerate! Notice the reduction in her lines and wrinkles (especially around her mouth). Her face is smooth and lifted.”\u003C\u002Fem> (Neurotris Facebook)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>SX3800\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“This is our premiere facial system. The SX3800 will allow you to treat the most challenging skin types who come into your treatment room. The power in the SX3800 is not matched in any other machine on the market. You will be able to lift, tone and tighten facial muscles for clients who have deep wrinkles and severe skin laxity.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“You will be able to help them to diminish the appearance of crow’s feet, the dreaded 11’s between the eyebrows, you can lift the mid-face to help reduce any sagging in the nasal labial fold, you can also lift drooping jowls and help to tighten up loose skin on the neck that can lead to the “turkey wattle.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The SX3800 can also improve and reduce the appearance of cellulite on the body. The Dynamic Microcurrent technology oxygenates the skin cells by increasing blood and lymphatic flow.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>SX4500\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“You will be able to lift, tone and tighten facial muscles for clients who have deep wrinkles and severe skin laxity.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“You can also help your clients find lift, toning and tightening in very specific areas of the face with the Infinity Probes. These are designed to help plump the lips to eliminate smokers lines around the mouth, they can be used around the eye to offer a lid lift and reduce under eye puffiness.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The proprietary body channel wavelength settings on the NeurotriS SX4500 are designed to induce lipolysis in the adipose tissue in the body. That means that the NeurotriS SX-4500 can send microcurrents into the fat cells that will cause them to burst and then die, thus, fat reduction.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>SVX650\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Incorporates 2 Functional Signal Technologies: Level 1 Lipolysis, for Shrinking Fat Cells; Lever 2 Toning, for Inch Loss &amp; Musclebuilding”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>PICO Toner\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“The Pico Toner comes standard with the highest quality Silver Toning gloves available today. You have the option to add toning probes and or facial toning pads to personalize your treatment needs. The toning gloves allows for more surface area to be treated as the probes can be used to treat fine areas. Use the Facial toning pads as a static treatment to focus on areas over the eye or nasolabial folds.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“The PICO Toner™ For Personal Facial &amp; Body Toning uses one AAA battery and has a long battery life. The smart feature built in automatically shuts off the unit after the 20 minute session.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have reviewed your firm’s response dated May 6, 2023, regarding your PICO Toner device and determined that it is not adequate. You state that the PICO Toner \u003Cem>“is manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fem> We reviewed FDA’s \u003Cem>Establishment Registration &amp; Device Listing\u003C\u002Fem> database, which notes premarket submission \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> as the 510(k) clearance number for devices with the following proprietary names: \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>, and \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>. Review of the \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> outlined within our \u003Cem>510(k) Premarket Notification\u003C\u002Fem> database showed that the \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> was cleared under \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> as a Transcutaneous Electric Nerve Stimulator (TENS), Class II under 21 CFR 882.5890 and product codes IPF and GZJ. As specified in the publicly available 510(k) Summary for the \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>, the device was cleared as a TENS device for symptomatic relief and management of chronic (long-term) intractable (not easily controlled) pain, and to help with the management of post-surgical and post-traumatic acute pain problems. As such, the device was not cleared for use on the face, or for aesthetic purposes. Therefore, the \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> would be subject to a new premarket notification, as would the PICO Toner, for the current marketed indications, as described in \u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov)\u003C\u002Fu>, which specifically states that changes to the type of joint, organ, bone, vasculature, or tissue to which a device is applied is likely to require submission of a new 510(k).\u003C\u002Fp>\n\n\u003Cp>We note that Transcutaneous Electric Nerve Simulation (TENS) units may have different intended uses and operating specifications. TENS units intended for aesthetic purposes are classified under \u003Cu>21 CFR 882.5890\u003C\u002Fu>, with product code NFO, considered a Class II device type, and subject to premarket notification. Due to the significant change in intended use as well as raising new questions of safety and effectiveness (i.e., cleared \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> nerve stimulation for pain relief under product codes GZJ versus a device for aesthetic purposes under product code NFO), a new premarket submission is required. Devices that are intended to be used on the face and for aesthetic purposes have much lower levels of stimulation output than TENS devices intended for pain relief such as that cleared under \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>. It is not clear that the device cleared under \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> could be safely and effectively used on the face, as there are risks associated with potential stimulation of facial nerves and eye or nerve damage due to the thinner skin of the face and the more proximal facial nerves.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Electrodes:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The original electrodes cleared for use with the Body System were self-adhesive pad applicators cleared under K970426. A review of your website and manuals shows that you are marketing additional accessories such as “Probes,” “Silver Facial Sculpting Gloves,” “Facial Pads,” and the “ANMA Lift”. These accessories appear to meet the definition of device under section 201(h) of the Act and are subject to premarket notification as they are electrodes that provide stimulation, which affects the structures of the body they contact. Cutaneous electrodes are regulated under 21 CFR 882.1320 (product code GXY). These additional accessories have different technological characteristics than those self-adhesive pad applicators cleared under K970426. Specifically, many of the currently marketed electrodes have different shapes and dimensions which can lead to a risk of non-uniform current distribution, higher current densities, and increase the risk of burns. Thus, there is potential for adverse events if the electrical response of the system and accessories has not been assessed. Furthermore, the additional accessories are composed of different materials than those cleared under K970426. This raises concerns of potential biological response because of unknown biocompatibility due to lack of assessment.\u003C\u002Fp>\n\n\u003Cp>Additionally, during our review we found multiple unsubstantiated promotional statements from your website that represent differences from that of the cleared electrode device labeling. These statements include the following (refers to website labeling unless otherwise noted):\u003C\u002Fp>\n\n\u003Cp>\u003Cu>ANMA Lift\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Purchase the ANMA Lift as an accessory to your existing SX Series NeurotriS Professional system or the Picotoner Home unit. This revolutionary dual probe fuels a highly effective facial massage tool with the technology of NeurotriS Dynamic Microcurrent to create a Lifting &amp; Sculpting Probe for any NeurotriS series systems in the treatment room that can be used on the face and body! You can use one or two probes.”\u003C\u002Fem>\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“This treatment has been called the “non-surgical facelift.”\u003C\u002Fem> (Neurotris Facebook)\u003C\u002Fli>\n\t\u003Cli>\u003Cem>“This revolutionary dual probe fuels a highly effective facial massage tool with the technology of NeurotriS Dynamic Microcurrent to create a Lifting &amp; Sculpting Probe for any NeurotriS series systems in the treatment room. What is your favorite way to treat the neck and jawline?”\u003C\u002Fem> (Neurotris Facebook)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>Silver Facial Sculpting Gloves\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Our Silver Facial Sculpting Gloves™ are designed to deliver the appropriate intrinsic dielectric property and promises a uniform disbursement of the Specific Frequency Signature (SFS) energy throughout the entire surface of the glove giving you Maximum Performance!”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>NEW Infinity Probes Pair vs 2\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cem>“Our NEW VERSION infinity probes are single channel probes used to treat smaller skin surface areas and for Iontophoresis. The Infinity probes are for all SX series facial machines &amp; the Pico Toner. The tips for the single probes are interchangeable for various sizes. Includes replaceable Probe cable that is User serviceable. NEW Medical grade High polish Stainless steel tips.”\u003C\u002Fem>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please note that iontophoresis devices, including associated electrodes as mentioned in the last claim listed above from the website, are regulated under \u003Cu>21 CFR 890.5525\u003C\u002Fu>. It does not appear that any such devices have been cleared for aesthetic purposes. Additionally, these devices have specific performance testing required prior to clearance, as described in the regulation. You do not appear to have a clearance for an iontophoresis device or associated accessories.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Gels &amp; Spray:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that your firm’s website and materials collected during the inspection include references to several conductive gels and sprays such as “Conductive Gel,” “Ion Spray,” and “Stem Cell Molecule Gel” that are not cleared with the device reviewed in K182440. Electroconductive media such as conductive spray and gel are a Class II medical device under 21 CFR 882.1275, product code GYB and are not exempt from 510(k) notification.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated May 6, 2023, regarding the conductive gels and spray is not adequate. Your firm has explained that the conductive gels &amp; spray are formulated by \u003Cstrong>(b)(6)\u003C\u002Fstrong> and that your firm plans to add these items to your FDA registration. However, no clearance number has been provided by your firm and these conductive gels and spray require a premarket submission. It is important to determine that the electroconductive properties of a new spray or gel are substantially equivalent to those of a predicate device and that all claims are either substantially equivalent to those previously cleared and\u002For supported by performance data (valid scientific evidence). Furthermore, there is a risk of adverse biological response to users if the biocompatibility safety of these sprays and gels has not been assessed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Body System medical devices (SX or SVX devices, PICO Toner) are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for design validation as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>Specifically, you had opened Corrective and Preventive Actions (CAPAs) 027 and 028 in 2021 to address issues with devices continuing to pulse with or without the start\u002Fstep push buttons being activated. These CAPAs described changes to the SX-3800 and SX-4500 devices. The CAPAs stated that validations were pending but you could not provide evidence of completion of validation of the design changes.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of the completion of validations and assessment as effective for these CAPA design changes.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for corrective and preventive action as required by 21 CFR 820.100.\u003C\u002Fp>\n\n\u003Cp>Specifically, you had opened CAPA 033 to address a light emitting diode (LED) light issue with your SX-4500 device and you corrected it by applying hot glue to exposed terminals. You closed the CAPA without evidence that the issue was effectively corrected. In addition, your CAPA procedure states that the Quality Manager will review customer complaints and initiate a Corrective Action Report. You stated that you (as owner) are responsible for complaint analysis, but you could not provide evidence that complaints were analyzed or trended.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of assessment as effective for CAPA 033 or that you perform complaint analyses per your CAPA procedure.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for rework as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\n\n\u003Cp>Specifically, your Control of Non-Conforming Product procedure requires that rework evaluation results be recorded or attached to the Non Conformance Report (NCR) file. For NCR 050, April 2021, the start\u002Fstop button on SX-3800 device switches not performing as intended, the disposition was documented as ‘rework’. You could not provide evidence of the rework\u002Fevaluation. Serial number 2200 of the device was released and shipped in July 2021 with the NCR still open.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of rework for your SX-3800 device in NCR 050.\u003C\u002Fp>\n\n\u003Cp>4. Failure to evaluate and select potential suppliers on their ability to meet specified requirements and define the type and extent of control to be exercised over suppliers as required by 21 CFR 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your Purchasing procedure, QP-706, Rev. 9 and Supplier Evaluation procedure, QP-705, Rev. 8, do not state the extent and type of control your firm has over your suppliers such as \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> is the manufacturer of the PICO Toner device and \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> is a supplier of gels and sprays used with Neurotris’ devices. You stated during the inspection that you have a “verbal and handshake agreement” with both suppliers. You have not documented any evaluation of \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> and you have failed to demonstrate how you used any evaluation to define the type and extent of control to be exercised over those suppliers.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of control over your suppliers \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem> other than to state that you “will work together” with these firms who “use a quality management system”.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 659244 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu-Nwaba, PharmD., MPH., MSc\u003Cbr>\nDeputy Director\u003Cbr>\nOHT5: Office of Neurological and Physical Medicine Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health Operations\u003Cbr>\nDivision 3\u002FWest\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAnthony “Tony” E. Picciano\n\nRecipient Title\n\nOwner\u002FPresident\n\nNeurotris, Inc. dba A1 Engineering\n\n30 Mauchly Ste A\n\nIrvine, CA 92618\n\nUnited States\n\ntony@neurotris.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 659244\n\nOctober 27, 2023\n\nDear Mr. Picciano:\n\nDuring an inspection of your firm, Neurotris, Inc. (Neurotris or NeurotriS or “the firm”), located in Irvine, CA, on April 4, 2023, through April 25, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of Class II Powered Muscle Stimulator devices such as the Neurotris SX or SVX Series Facial Body Systems, which may also be referred to as the Neurotris Body System. These medical devices include, but are not limited to, the SX2500 (Picowave), SX3800, SX4500, SVX650, PICO Toner, and accessories such as electrodes, conductive gels, and spray. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received your response, dated May 6, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nMisbranded and\u002For Unapproved Device Violations\n\nOur inspection and review of the available information, including the firm’s website, www.neurotris.com, revealed that the Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, PICO Toner, and accessories such as electrodes (ANMA lift, Probes, Silver Facial Sculpting Gloves, Facial Pads), conductive gels, and spray, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for these devices as described and marketed. The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)(1)).\n\nYou currently have a clearance for the Body System (models SX101 and 0S2911) dated February 26, 2019, as a prescription device, under K182440. The Body System was cleared as a Powered Muscle Stimulator for muscle conditioning under 21 CFR 890.5850 product code NGX for the following indications:\n\n“The Body System is intended for muscle conditioning to stimulate healthy muscles. The Body System is not intended to be used in conjunction with therapy or treatment of medical diseases or medical conditions of any kind. The Body System is intended to be operated by a trained professional who is present to monitor treatment.”\n\nBased on the evidence reviewed at the April 2023 inspection and other available information, including statements on your firm’s website [https:\u002F\u002Fwww.neurotris.com] and social media [Facebook], last reviewed on August 13, 2023, as described below, the devices cited in this letter have intended uses that exceed or otherwise differ from your 510(k) clearance for the Body System device and the classification codified at 21 CFR 890.5850, such that premarket notification is required prior to introduction or delivery for introduction of these devices into interstate commerce for commercial distribution per 21 CFR 807.81(a). Additionally, your devices appear to have different technological characteristics than the original 510(k) cleared device, including, among others, differences in power sources, number of channels, and device accessories, which could significantly affect the safety or effectiveness of the device. Further, the following changes represent significant changes or modifications outside the scope of the K182440 clearance in the design, components, method of manufacture, or intended use of your cleared device, which could also significantly affect its safety and effectiveness.\n\nNeurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner:\n\nThe original Body System devices (models SX101 and 0S2911) were cleared under K182440. A review of your website and manuals for your current Neurotris devices, the SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner show that these new devices have different technical characteristics than those of the SX101 and OS2911. These differences include variations between the number of channels compared to the cleared devices. In addition, models SX101 and OS2911 are mains powered but the PICO Toner II is battery powered. It also appears that the circuitry of the devices may be different from the cleared device. All of these changes in the technical characteristics create potential differences in the electrical safety and electromagnetic compatibility of your devices compared to the tested and cleared device, which may lead to risks associated with electric shock, excessive temperatures, burns, and interference. Such changes and modifications could significantly affect the safety and effectiveness of these devices. Therefore, such technical differences would require a new 510(k).\n\nAdditionally, there are significant differences between how your originally cleared devices and the new devices are intended to be used, according to the labeling. As described in “Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff” (fda.gov), changes to labeling, including the Indications for Use, require review in a new 510(k). The guidance notes that the decision to submit a new 510(k) may apply not only to changes to the indications for use statement of the labeling, but also to changes to other sections of the labeling, such as the directions for use of the device. The original devices were cleared as Powered Muscle Stimulators for muscle conditioning under 21 CFR 890.5850 product code NGX. The cleared indication for use states, “The Body System is intended for muscle conditioning to stimulate healthy muscles.” However, a review of your Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner manuals show that the intended use of these devices is “to stimulate nerves and muscles, causing muscle contraction for esthetic beautification.” The stimulation of nerves for aesthetic purposes is a significant change in how and where the device is intended to be used from your cleared 510(k) device. Stimulation of nerves as opposed to muscles raises new questions of safety and effectiveness requiring FDA review prior to marketing. Additionally, stimulation of nerves exceeds the intended use definition of devices classified under 21 CFR 890.5850 for powered muscle stimulators.\n\nFurthermore, there is significant risk related to the new anatomical areas of use that are promoted by your firm. The original cleared Body System manuals (models SX101 and 0S2911) have the following warnings against use on the chest, significant portions of the face, and neck:\n\n“Stimulation should not be applied over the neck or mouth. Severe spasm of the laryngeal and pharyngeal muscles may occur and the contractions may be strong enough to close the airway or cause difficulty in breathing.”\n\n“Stimulation should not be applied transthoracically in that the introduction of electrical current in the heart may cause cardiac arrhythmias”\n\n“Stimulation should not be applied transcerebrally\"\n\nYet, multiple statements on your firm’s website, social media, and user manuals promote the use of Neurotris SX2500 (Picowave), SX3800, SX4500, SVX650, and PICO Toner on these prohibited areas.\n\nExamples of promotional statements from your website, social media, and manual that are beyond the clearance of your device under 21 CFR 890.5850 for Powered Muscle Stimulators include but are not limited to (refers to Neurotris website labeling unless otherwise noted):\n\nSX2500 (Picowave)\n\nAuto Mode 2 BUILD (FACE LIFTING) (Manual)\n\n“This client is having an amazing result with NEUROTRIS Picowave Microcurrent and Rezenerate! Notice the reduction in her lines and wrinkles (especially around her mouth). Her face is smooth and lifted.” (Neurotris Facebook)\n\nSX3800\n\n“This is our premiere facial system. The SX3800 will allow you to treat the most challenging skin types who come into your treatment room. The power in the SX3800 is not matched in any other machine on the market. You will be able to lift, tone and tighten facial muscles for clients who have deep wrinkles and severe skin laxity.”\n\n“You will be able to help them to diminish the appearance of crow’s feet, the dreaded 11’s between the eyebrows, you can lift the mid-face to help reduce any sagging in the nasal labial fold, you can also lift drooping jowls and help to tighten up loose skin on the neck that can lead to the “turkey wattle.”\n\n“The SX3800 can also improve and reduce the appearance of cellulite on the body. The Dynamic Microcurrent technology oxygenates the skin cells by increasing blood and lymphatic flow.”\n\nSX4500\n\n“You will be able to lift, tone and tighten facial muscles for clients who have deep wrinkles and severe skin laxity.”\n\n“You can also help your clients find lift, toning and tightening in very specific areas of the face with the Infinity Probes. These are designed to help plump the lips to eliminate smokers lines around the mouth, they can be used around the eye to offer a lid lift and reduce under eye puffiness.”\n\n“The proprietary body channel wavelength settings on the NeurotriS SX4500 are designed to induce lipolysis in the adipose tissue in the body. That means that the NeurotriS SX-4500 can send microcurrents into the fat cells that will cause them to burst and then die, thus, fat reduction.”\n\nSVX650\n\n“Incorporates 2 Functional Signal Technologies: Level 1 Lipolysis, for Shrinking Fat Cells; Lever 2 Toning, for Inch Loss & Musclebuilding”\n\nPICO Toner\n\n“The Pico Toner comes standard with the highest quality Silver Toning gloves available today. You have the option to add toning probes and or facial toning pads to personalize your treatment needs. The toning gloves allows for more surface area to be treated as the probes can be used to treat fine areas. Use the Facial toning pads as a static treatment to focus on areas over the eye or nasolabial folds.”\n\n“The PICO Toner™ For Personal Facial & Body Toning uses one AAA battery and has a long battery life. The smart feature built in automatically shuts off the unit after the 20 minute session.”\n\nWe have reviewed your firm’s response dated May 6, 2023, regarding your PICO Toner device and determined that it is not adequate. You state that the PICO Toner “is manufactured by (b)(4).” We reviewed FDA’s Establishment Registration & Device Listing database, which notes premarket submission (b)(4) as the 510(k) clearance number for devices with the following proprietary names: (b)(4), and (b)(4). Review of the (b)(4) outlined within our 510(k) Premarket Notification database showed that the (b)(4) was cleared under (b)(4) as a Transcutaneous Electric Nerve Stimulator (TENS), Class II under 21 CFR 882.5890 and product codes IPF and GZJ. As specified in the publicly available 510(k) Summary for the (b)(4), the device was cleared as a TENS device for symptomatic relief and management of chronic (long-term) intractable (not easily controlled) pain, and to help with the management of post-surgical and post-traumatic acute pain problems. As such, the device was not cleared for use on the face, or for aesthetic purposes. Therefore, the (b)(4) would be subject to a new premarket notification, as would the PICO Toner, for the current marketed indications, as described in Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov), which specifically states that changes to the type of joint, organ, bone, vasculature, or tissue to which a device is applied is likely to require submission of a new 510(k).\n\nWe note that Transcutaneous Electric Nerve Simulation (TENS) units may have different intended uses and operating specifications. TENS units intended for aesthetic purposes are classified under 21 CFR 882.5890, with product code NFO, considered a Class II device type, and subject to premarket notification. Due to the significant change in intended use as well as raising new questions of safety and effectiveness (i.e., cleared (b)(4) nerve stimulation for pain relief under product codes GZJ versus a device for aesthetic purposes under product code NFO), a new premarket submission is required. Devices that are intended to be used on the face and for aesthetic purposes have much lower levels of stimulation output than TENS devices intended for pain relief such as that cleared under (b)(4). It is not clear that the device cleared under (b)(4) could be safely and effectively used on the face, as there are risks associated with potential stimulation of facial nerves and eye or nerve damage due to the thinner skin of the face and the more proximal facial nerves.\n\nElectrodes:\n\nThe original electrodes cleared for use with the Body System were self-adhesive pad applicators cleared under K970426. A review of your website and manuals shows that you are marketing additional accessories such as “Probes,” “Silver Facial Sculpting Gloves,” “Facial Pads,” and the “ANMA Lift”. These accessories appear to meet the definition of device under section 201(h) of the Act and are subject to premarket notification as they are electrodes that provide stimulation, which affects the structures of the body they contact. Cutaneous electrodes are regulated under 21 CFR 882.1320 (product code GXY). These additional accessories have different technological characteristics than those self-adhesive pad applicators cleared under K970426. Specifically, many of the currently marketed electrodes have different shapes and dimensions which can lead to a risk of non-uniform current distribution, higher current densities, and increase the risk of burns. Thus, there is potential for adverse events if the electrical response of the system and accessories has not been assessed. Furthermore, the additional accessories are composed of different materials than those cleared under K970426. This raises concerns of potential biological response because of unknown biocompatibility due to lack of assessment.\n\nAdditionally, during our review we found multiple unsubstantiated promotional statements from your website that represent differences from that of the cleared electrode device labeling. These statements include the following (refers to website labeling unless otherwise noted):\n\nANMA Lift\n\n“Purchase the ANMA Lift as an accessory to your existing SX Series NeurotriS Professional system or the Picotoner Home unit. This revolutionary dual probe fuels a highly effective facial massage tool with the technology of NeurotriS Dynamic Microcurrent to create a Lifting & Sculpting Probe for any NeurotriS series systems in the treatment room that can be used on the face and body! You can use one or two probes.”\n\n“This treatment has been called the “non-surgical facelift.” (Neurotris Facebook)\n\n“This revolutionary dual probe fuels a highly effective facial massage tool with the technology of NeurotriS Dynamic Microcurrent to create a Lifting & Sculpting Probe for any NeurotriS series systems in the treatment room. What is your favorite way to treat the neck and jawline?” (Neurotris Facebook)\n\nSilver Facial Sculpting Gloves\n\n“Our Silver Facial Sculpting Gloves™ are designed to deliver the appropriate intrinsic dielectric property and promises a uniform disbursement of the Specific Frequency Signature (SFS) energy throughout the entire surface of the glove giving you Maximum Performance!”\n\nNEW Infinity Probes Pair vs 2\n\n“Our NEW VERSION infinity probes are single channel probes used to treat smaller skin surface areas and for Iontophoresis. The Infinity probes are for all SX series facial machines & the Pico Toner. The tips for the single probes are interchangeable for various sizes. Includes replaceable Probe cable that is User serviceable. NEW Medical grade High polish Stainless steel tips.”\n\nPlease note that iontophoresis devices, including associated electrodes as mentioned in the last claim listed above from the website, are regulated under 21 CFR 890.5525. It does not appear that any such devices have been cleared for aesthetic purposes. Additionally, these devices have specific performance testing required prior to clearance, as described in the regulation. You do not appear to have a clearance for an iontophoresis device or associated accessories.\n\nGels & Spray:\n\nWe note that your firm’s website and materials collected during the inspection include references to several conductive gels and sprays such as “Conductive Gel,” “Ion Spray,” and “Stem Cell Molecule Gel” that are not cleared with the device reviewed in K182440. Electroconductive media such as conductive spray and gel are a Class II medical device under 21 CFR 882.1275, product code GYB and are not exempt from 510(k) notification.\n\nYour firm’s response dated May 6, 2023, regarding the conductive gels and spray is not adequate. Your firm has explained that the conductive gels & spray are formulated by (b)(6) and that your firm plans to add these items to your FDA registration. However, no clearance number has been provided by your firm and these conductive gels and spray require a premarket submission. It is important to determine that the electroconductive properties of a new spray or gel are substantially equivalent to those of a predicate device and that all claims are either substantially equivalent to those previously cleared and\u002For supported by performance data (valid scientific evidence). Furthermore, there is a risk of adverse biological response to users if the biocompatibility safety of these sprays and gels has not been assessed.\n\nQuality System Regulation (QSR) Violations\n\nOur inspection also revealed that the Body System medical devices (SX or SVX devices, PICO Toner) are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for design validation as required by 21 CFR 820.30(g).\n\nSpecifically, you had opened Corrective and Preventive Actions (CAPAs) 027 and 028 in 2021 to address issues with devices continuing to pulse with or without the start\u002Fstep push buttons being activated. These CAPAs described changes to the SX-3800 and SX-4500 devices. The CAPAs stated that validations were pending but you could not provide evidence of completion of validation of the design changes.\n\nWe have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of the completion of validations and assessment as effective for these CAPA design changes.\n\n2. Failure to adequately establish and maintain procedures for corrective and preventive action as required by 21 CFR 820.100.\n\nSpecifically, you had opened CAPA 033 to address a light emitting diode (LED) light issue with your SX-4500 device and you corrected it by applying hot glue to exposed terminals. You closed the CAPA without evidence that the issue was effectively corrected. In addition, your CAPA procedure states that the Quality Manager will review customer complaints and initiate a Corrective Action Report. You stated that you (as owner) are responsible for complaint analysis, but you could not provide evidence that complaints were analyzed or trended.\n\nWe have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of assessment as effective for CAPA 033 or that you perform complaint analyses per your CAPA procedure.\n\n3. Failure to adequately establish and maintain procedures for rework as required by 21 CFR 820.90(b)(2).\n\nSpecifically, your Control of Non-Conforming Product procedure requires that rework evaluation results be recorded or attached to the Non Conformance Report (NCR) file. For NCR 050, April 2021, the start\u002Fstop button on SX-3800 device switches not performing as intended, the disposition was documented as ‘rework’. You could not provide evidence of the rework\u002Fevaluation. Serial number 2200 of the device was released and shipped in July 2021 with the NCR still open.\n\nWe have reviewed your firm’s response and concluded that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of rework for your SX-3800 device in NCR 050.\n\n4. Failure to evaluate and select potential suppliers on their ability to meet specified requirements and define the type and extent of control to be exercised over suppliers as required by 21 CFR 820.50(a).\n\nSpecifically, your Purchasing procedure, QP-706, Rev. 9 and Supplier Evaluation procedure, QP-705, Rev. 8, do not state the extent and type of control your firm has over your suppliers such as (b)(4) is the manufacturer of the PICO Toner device and (b)(4) is a supplier of gels and sprays used with Neurotris’ devices. You stated during the inspection that you have a “verbal and handshake agreement” with both suppliers. You have not documented any evaluation of (b)(4) and you have failed to demonstrate how you used any evaluation to define the type and extent of control to be exercised over those suppliers.\n\nWe reviewed your firm’s response and conclude that it is not adequate. You stated that you “promise to correct” but you did not provide any documentation of control over your suppliers (b)(4) other than to state that you “will work together” with these firms who “use a quality management system”.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 659244 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD., MPH., MSc\n\nDeputy Director\n\nOHT5: Office of Neurological and Physical Medicine Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health Operations\n\nDivision 3\u002FWest","Neurotris, Inc. dba A1 Engineering","neurotris-inc-dba-a1-engineering-659244-10272023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fneurotris-inc-dba-a1-engineering-659244-10272023","2026-10-26T08:09:32.096269+00:00","2023-11-07","659244","Anthony “Tony” E. Picciano","2026-08-20T00:33:29.391+00:00","VIA UNITED PARCEL SERVICE","2023-10-27",{"id":97,"raw":98,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":112,"product_type":70,"closeout_date":19,"issuing_office":102,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":19,"reference_number":116,"action_taken_date":117,"medical_device_id":19,"response_letter_date":19},131,[99,100,101,102,103,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026\">HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-05-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leah R. Hanson, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Neuroscience Research\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>295 Phalen Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55130-2455\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-05-02\u003C\u002Fp>\u003Cp>Dear Dr. Hanson:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for sponsor-investigator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (formerly performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, the protocol and final study report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated that the test article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4) \u003C\u002Fstrong>(0.5 mg, 5 mg, and 10 mg, respectively), and for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot used in study \u003Cstrong>(b)(4)\u003C\u002Fstrong>; (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.&nbsp;\u003C\u002Fp>\u003Cp>In addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Your testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations were not accurately documented in the final study report:\u003C\u002Fp>\u003Cp>a. The deaths of two male rats (Rats #41 and #42 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group) during the conduct of the study were not reflected in the final study report.\u003C\u002Fp>\u003Cp>b. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group.\u003C\u002Fp>\u003Cp>c. Female Rat #84 in the 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Testing facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, during the conduct of nonclinical laboratory studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\u003C\u002Fp>\u003Cul>\u003Cli>Hematology test results for male and female rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Serum chemistry test results for male rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hematology test results for male and female rabbits for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> or rabbit blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\u003C\u002Fp>\u003Cp>a. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\u003C\u002Fp>\u003Cp>b. Test system observations\u003C\u002Fp>\u003Cp>c. Laboratory tests\u003C\u002Fp>\u003Cp>d. Handling of animals found to be moribund or dead during a study\u003C\u002Fp>\u003Cp>e. Collection and identification of specimens\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs \u003Cem>before\u003C\u002Fem> conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\u003C\u002Fp>\u003Cp>As evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>05\u002F19\u002F2026 12:58:47 PM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-05-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeah R. Hanson, Ph.D.\n\nRecipient Title\n\nSenior Director, Neuroscience Research\n\nHealthPartners Neuroscience Center Research and Innovation\n\n295 Phalen Boulevard\n\nSaint Paul, MN 55130-2455\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-05-02\nDear Dr. Hanson:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug (b)(4), performed for sponsor-investigator (b)(4) (formerly performed for (b)(4)).\nProtocol (b)(4): “(b)(4)”\nProtocol (b)(4): “(b)(4)”\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\n1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\nThe testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\nSpecifically, the protocol and final study report for Study (b)(4) stated that the test article, (b)(4), was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% (b)(4) (0.5 mg, 5 mg, and 10 mg, respectively), and for Study (b)(4), to a final dose concentration of 1%, 10%, or 20% (b)(4) (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies (b)(4) and (b)(4).\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the (b)(4) lot used in study (b)(4); (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.\nIn addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\nYour testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\n2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol (b)(4), the following observations were not accurately documented in the final study report:\na. The deaths of two male rats (Rats #41 and #42 in the 10% (b)(4) dosing group) during the conduct of the study were not reflected in the final study report.\nb. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% (b)(4) dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% (b)(4) dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% (b)(4) dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% (b)(4) dosing group.\nc. Female Rat #84 in the 20% (b)(4) dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\nIn your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\nTesting facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\nSpecifically, during the conduct of nonclinical laboratory studies (b)(4) and (b)(4), the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\nHematology test results for male and female rats for Protocol (b)(4)\nSerum chemistry test results for male rats for Protocol (b)(4)\nHematology test results for male and female rabbits for Protocol (b)(4)\nAdditionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol (b)(4) or rabbit blood in Protocol (b)(4).\nWe acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol (b)(4). Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\nIn your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\nWhile we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\nA testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\na. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\nb. Test system observations\nc. Laboratory tests\nd. Handling of animals found to be moribund or dead during a study\ne. Collection and identification of specimens\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs before conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\nAs evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n05\u002F19\u002F2026 12:58:47 PM","HealthPartners Neuroscience Center Research and Innovation","healthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-10-26T08:08:53.733946+00:00","2026-06-02","725333","Leah R. Hanson, Ph.D.","2026-08-19T04:39:07.121+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-05-02","2026-05-19",5,{"510k":120,"classification":121,"enforcement":122,"event":123,"event_backfill":124,"pma":125,"warning_letter":126},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]